Oseukotek announced on the 6th that it had confirmed on the 4th (local time) that its largest shareholder, Advisor Kim Junggeun, passed away in the United States.


Advisor Kim was the founder of Oseukotek, the original developer of Leclaza, the first domestically developed anticancer drug to receive approval from the U.S. Food and Drug Administration (FDA), and he was the largest shareholder with a 12.45% stake.


Kim Jeonggeun, CEO of Oscotec

Kim Jeonggeun, CEO of Oscotec

View original image

Advisor Kim earned his bachelor's, master's, and doctoral degrees in dentistry from Seoul National University in February 1960, and went on to serve as a visiting professor of oral biology at Harvard School of Dental Medicine in the United States, a chair professor in the Department of Biochemistry at Dankook University College of Dentistry, the head of the Korea Institute for Biomaterials, and a board member of the Korea Bio Venture Association.


After founding Oseukotek in 1998, he served as CEO until he failed to be reappointed as CEO at the shareholders' meeting in March last year due to shareholder opposition to the separate listing plan of subsidiary Genosco, after which he took on the role of advisor.


Oseukotek stated that details such as the final allocation of shares and the identity of the largest shareholder following inheritance have not yet been finalized, and that it plans to file corrections or additional disclosures in accordance with relevant laws and regulations as soon as the details are confirmed.



Oseukotek stressed that under the current management and board of directors, it plans to carry out key work, including business operations and research and development, in a stable manner as planned.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing